Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Stephens

Showing results (71-80 of 168) with videos related to

Pageof 17
Sort By:
Oncoscience|August 6, 2015
Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplificationUmut Disel, Alexis Germain, Bahar Yilmazel, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2015
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKISamuel J Klempner, Lyudmila A Bazhenova, Fadi S Braiteh, et al.
Cancer|December 10, 2015
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Kai Wang, Depinder Khaira, et al.
Clinical Breast Cancer|January 13, 2018
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid BiopsyErica L Gornstein, Sara Sandefur, Jon H Chung, et al.
Oncotarget|May 24, 2016
Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaMonika Joshi, Monali Vasekar, Petros Grivas, et al.
Gastroenterology|April 12, 2016
Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel DiseaseRona Yaeger, Manish A Shah, Vincent A Miller, et al.
The Oncologist|March 12, 2017
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> AlterationJulia A Elvin, Laurie M Gay, Rita Ort, et al.
Journal of Pediatric Hematology/Oncology|March 25, 2017
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil ImmunotherapyMaurizio Ghisoli, McCarley Rutledge, Philip J Stephens, et al.
Cancer|June 6, 2017
Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapySiraj M Ali, Ming Yao, Jicheng Yao, et al.
Human Pathology|October 29, 2017
General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling studyHwajeong Lee, Tony El Jabbour, Sanaz Ainechi, et al.
Pageof 17

Showing results (71-80 of 168) with videos related to

Sort By:
Pageof 17
Oncoscience|August 6, 2015
Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplificationUmut Disel, Alexis Germain, Bahar Yilmazel, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2015
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKISamuel J Klempner, Lyudmila A Bazhenova, Fadi S Braiteh, et al.
Cancer|December 10, 2015
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Kai Wang, Depinder Khaira, et al.
Clinical Breast Cancer|January 13, 2018
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid BiopsyErica L Gornstein, Sara Sandefur, Jon H Chung, et al.
Oncotarget|May 24, 2016
Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaMonika Joshi, Monali Vasekar, Petros Grivas, et al.
Gastroenterology|April 12, 2016
Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel DiseaseRona Yaeger, Manish A Shah, Vincent A Miller, et al.
The Oncologist|March 12, 2017
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> AlterationJulia A Elvin, Laurie M Gay, Rita Ort, et al.
Journal of Pediatric Hematology/Oncology|March 25, 2017
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil ImmunotherapyMaurizio Ghisoli, McCarley Rutledge, Philip J Stephens, et al.
Cancer|June 6, 2017
Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapySiraj M Ali, Ming Yao, Jicheng Yao, et al.
Human Pathology|October 29, 2017
General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling studyHwajeong Lee, Tony El Jabbour, Sanaz Ainechi, et al.
Pageof 17